Close Menu

NEW YORK – Cancer genetics testing lab firm NeoGenomics said on Wednesday that it has acquired Trapelo Health for $65 million, consisting of $35 million in cash on hand and $30 million in NeoGenomics' common stock.

Fort Myers, Florida-based NeoGenomics will offer Burlington, Massachusetts-based Trapelo's clinical decision support system to providers, payors, and labs to aid precision oncology across all healthcare settings.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.